The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fox, S. W.
Right arrow Articles by Chambers, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fox, S. W.
Right arrow Articles by Chambers, T. J.
Right arrowPubmed/NCBI databases
*Substance via MeSH
The Journal of Immunology, 2003, 170: 3679-3687.
Copyright © 2003 by The American Association of Immunologists

The Possible Role of TGF-{beta}-Induced Suppressors of Cytokine Signaling Expression in Osteoclast/Macrophage Lineage Commitment In Vitro1

Simon W. Fox2,*, S. Jaharul Haque{dagger}, Alison C. Lovibond* and Timothy J. Chambers*

* Department of Cellular Pathology, St. George’s Hospital Medical School, London, United Kingdom; and {dagger} Departments of Cancer Biology and Pulmonary Critical Care Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Osteoclast formation is dependent on the ability of TGF-{beta} to enable receptor activator of NF-{kappa}B ligand (RANKL)-induced commitment of hemopoietic precursors to the osteoclastic lineage. The mechanism by which TGF-{beta} enables formation is unknown. One possibility is that TGF-{beta} opposes Janus kinase (JAK)/STAT signals generated by inhibitory cytokines such as IFN-{beta}. The JAK/STAT pathway is activated by cytokines that induce resistance to osteoclast formation, such as IFN-{gamma} and M-CSF, and the effect of these is opposed by TGF-{beta}. Recently, a group of STAT-induced factors, termed suppressors of cytokine signaling (SOCS), has been identified that inhibit JAK/STAT signals. Therefore, we tested the ability of TGF-{beta} to induce SOCS expression in osteoclast precursors and examined the effect of SOCS expression on osteoclast/macrophage lineage commitment. We found that while SOCS mRNA is undetectable in macrophages, osteoclasts express SOCS-3, and TGF-{beta} up-regulates this expression. Furthermore, TGF-{beta} rapidly induces sustained SOCS-3 expression in macrophage/osteoclast precursors. To determine whether SOCS-3 plays a role in osteoclast differentiation we expressed SOCS-3 in precursors using a retroviral system. We found that osteoclast differentiation was significantly enhanced in SOCS-3-infected precursors, and SOCS-3 expression enables formation in the presence of anti-TGF-{beta} Ab. On the other hand, antisense knockdown of SOCS-3 strongly suppressed osteoclast formation and significantly blunted the response to TGF-{beta}. Moreover, like TGF-{beta}, SOCS-3 expression opposed the inhibitory effect of IFN-{beta}. These data suggest that TGF-{beta}-induced expression of SOCS-3 may represent a mechanism by which TGF-{beta} suppresses inhibitory cytokine signaling, priming precursors for a role in bone resorption.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
The osteoclast is the cell that resorbs bone. Overactivity by this cell is responsible for the excessive bone loss seen in osteoporosis and other common clinical conditions. It has become clear that receptor activator of NF-{kappa}B ligand (RANKL),3 an osteoblast-expressed member of the TNF superfamily, induces osteoclast differentiation and activity in cells of the mononuclear phagocyte lineage (1, 2). However, while RANKL plays a central role in osteoclast formation, only a proportion of mononuclear phagocyte precursors form osteoclasts when incubated with RANKL in vitro (3, 4). In addition, in semisolid cultures, osteoclasts that develop in colonies are always mixed with macrophages (5), suggesting that RANKL alone might not be sufficient to ensure that precursors become osteoclasts at sites of resorption.

Responses to stimuli from the TNF superfamily are characteristically associated with critical inputs from other factors (6). One such factor that influences response to TNFs is TGF-{beta}, which is the most abundant cytokine found in bone matrix. Interestingly, TGF-{beta}, like other members of the TGF-{beta} superfamily (7, 8), significantly augments RANKL-induced osteoclast formation (4, 9). Furthermore, RANKL-induced osteoclast formation is abolished by recombinant soluble TGF-{beta} type II receptors or anti-TGF-{beta} Abs, suggesting that osteoclasts induced by RANKL without the addition of exogenous TGF-{beta} are dependent on TGF-{beta} present in the culture medium or produced by the precursors themselves (4).

It appears that the primary role of TGF-{beta} in osteoclast formation is to maintain and enhance the responsiveness of osteoclast precursors to RANKL (4). Thus, TGF-{beta} prevents the increased resistance of mononuclear phagocyte precursors to RANKL-induced osteoclast formation that occurs when precursors are incubated in M-CSF alone (3, 4, 5). This is consistent with a model in which connective tissue matrix or bone cells release TGF-{beta}, which maintains RANKL responsiveness in precursors during migration to areas of prospective resorption, where they are activated to form osteoclasts by RANKL-expressing osteoblasts (1). However, the mechanism by which TGF-{beta} maintains the responsiveness of osteoclast precursors to RANKL is at present unknown. One possibility is that cells perceive the culture environment as essentially inflammatory (10, 11, 12), and that TGF-{beta}, which has anti-inflammatory actions on the mononuclear phagocyte system, opposes these macrophage-activating influences. Consistent with this, several cytokines produced by macrophages in vitro have been shown to inhibit osteoclast formation (13). In particular, it has been shown that RANKL induces IFN-{beta} expression, which inhibits osteoclast formation and has been proposed to act as an autocrine regulator of osteoclast formation (14). In addition, we have shown that IFN-{gamma} directly inhibits osteoclast formation by priming precursors for a role as cytocidal macrophages, activating NO production while strongly suppressing osteoclast formation (15, 16). TGF-{beta} opposes both actions of IFN-{gamma}.

IFN-{gamma} and IFN-{beta}, like other factors that can suppress osteoclast formation, such as M-CSF and GM-CSF (17, 18), signal through the Janus kinase (JAK)/STAT pathway (19, 20). Furthermore, the anti-osteoclastic action of several of these cytokines is absent in mice lacking STATs (14, 20, 21). Thus, JAK/STAT activation may represent a central mechanism by which inhibitory cytokines suppress osteoclast formation, and TGF-{beta} might therefore act to block JAK/STAT signals to enable formation.

Recently, a group of cytokine-inducible factors (suppressors of cytokine signaling (SOCS)) has been discovered that forms part of the negative feedback mechanisms that inhibit the JAK/STAT pathway after cytokine stimulation (22, 23, 24, 25, 26). Most, if not all, members of the cytokine superfamily rapidly induce transcriptional activation of one or more SOCS, which further block JAK/STAT activity and thus prevent overstimulation (24). The prototype of this family, SOCS-1, was identified by its ability to inhibit macrophage differentiation of M1 cells in response to IL-6 (22). Database searches have since identified at least an additional 14 members of this family, all of which contain a highly conserved 40-aa domain at the C terminus termed the SOCS box (27). Cytokines such as IL-3, IL-4, IL-13, GM-CSF, IFN-{beta}, and IFN-{gamma} induce SOCS expression in numerous cells, including bone marrow cells (22), via a STAT-dependent transcriptional mechanism.

Intriguingly, SOCS expression has been shown to inhibit the activity of several factors that act via JAK/STAT signaling. In view of this, we elected to determine whether TGF-{beta} induces SOCS expression in noncommitted precursors, and whether such SOCS signals could direct precursors to the osteoclastic lineage rather than to alternative cytocidal and inflammatory pathways.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Media and reagents

Nonadherent, M-CSF-dependent bone marrow cells were incubated in MEM with Earle’s salts (EMEM) supplemented with 10% FBS, 2 mmol/liter glutamine, 100 IU/ml benzylpenicillin, and 100 µg/ml streptomycin (all from Imperial Laboratories, Andover, U.K.). The Phoenix retroviral packaging cell line (28) was incubated in DMEM supplemented with 10% FBS and 2 mmol/liter glutamine, 100 IU/ml benzylpenicillin, and 100 µg/ml streptomycin. Incubations were performed at 37°C in 5% CO2, and cultures fed every 2–3 days. Recombinant human TGF-{beta}1, pan-specific TGF-{beta} Ab, and recombinant murine IFN-{beta} were obtained from R&D Systems (Minneapolis, MN). Recombinant human M-CSF was provided by Chiron (Emeryville, CA), and soluble recombinant human RANKL was obtained from Insight Biotechnology (Wembley, Middlesex, U.K.). Slices of bovine cortical bone were prepared as previously described (29). Bone slices were cut with a low speed diamond saw, cleaned by ultrasonication in water, washed briefly in acetone, immersed in ethanol for 10 min, and stored dry at room temperature.

Isolation of stroma-depleted, nonadherent M-CSF-dependent bone marrow precursors

Male MF-1 mice (4–6 wk old) were killed by cervical dislocation. Femora were removed and dissected free of adherent soft tissue. The bone ends were cut, and the marrow was flushed out with medium 199 (Imperial) by injecting medium at one end of the bone with a 21-gauge needle. The bone marrow cells were washed twice, resuspended in EMEM, and incubated for 24 h in M-CSF (5 ng/ml) at a density of 3 x 105/ml in a 75-cm2 flask. After 24 h, nonadherent cells were harvested, washed, and incubated as described below.

Northern analysis of SOCS expression

Total RNA was prepared from M-CSF-dependent bone marrow precursors incubated (3 x 104/ml) for 5 days in 75-cm2 tissue culture flasks in EMEM containing M-CSF (30 ng/ml) with combinations of TGF-{beta}1 (0.1 ng/ml) and RANKL (30 ng/ml), according to an established method (30). For Northern blot analysis, 15 µg of total RNA was separated on a 1.2% agarose-formaldehyde gel, transferred to a Hybond-N membrane (Amersham International, Little Chalfont, U.K.), and hybridized with specific 32P-labeled cDNA probes for murine SOCS-1 (724 bp), SOCS-2 (679 bp), SOCS-3 (760 bp), cytokine-inducible gene (CIS; 740 bp), and {beta}-actin (760 bp) prepared by the random primer method (Amersham International). Specific murine SOCS probes were prepared by excising cDNA inserts from expression vectors (31), using appropriate digestion enzymes. After hybridization the membrane was washed (2x SSPE and 0.1% SDS, twice for 15 min each time; 1x SSPE and 0.1% SDS, 30 min; 0.5x sodium chloride sodium phosphate EDTA (SSPE) and 0.1% SDS, twice for 15 min each time; all at 42°C) and autoradiographed using Hyperfilm (Amersham International).

Quantitative RT-PCR

Nonadherent, M-CSF-dependent bone marrow cells (3 x 104/ml) were incubated for 2 days in 75-cm2 tissue culture flasks in EMEM containing M-CSF (10 ng/ml). Cultures were then treated with TGF-{beta}1 (0.1 ng/ml) and/or RANKL (30 ng/ml) for 1–24 h, and total RNA was extracted. For assessment of RNA expression, 2 µg of total RNA was reverse transcribed for 1 h at 42°C using 100 pmol of random hexamers (Amersham International) and 600 U of Moloney murine leukemia virus (Life Technologies, Paisley, U.K.) in a 50-µl reaction. This was then diluted to a final volume of 100 µl.

Real-time PCR was conducted with the I-Cycler (Bio-Rad, Hemel Hempstead, U.K.) using the DNA-binding dye SYBR Green for the detection of PCR products. Two microliters of either external plasmid standards or cDNA (equal to 40 ng of total RNA) was added to a final reaction volume of 25 µl containing 200 µM dNTPs, 200 µM primers, 0.25 U of AmpErase UNG (PE Applied Biosystems, Warrington, U.K.), 2.5 µl of 10x SYBR Green PCR buffer, 3 mM MgCl2, and 0.625 U of platinum Taq polymerase (Universal PCR Master mix; PE Applied Biosystems). This was then made up to 100 µl, and 2 µl of this was used as a template for 25-µl PCR reactions. Primers used for PCR were as follows: SOCS-3 sense, 5'-GAACCTACGCATCCAGTGTGAG-3'; SOCS-3 antisense, 5'-CGTTGACAGTCTTCCGACAAAG-3'; {beta}-actin sense, 5'-GTCATCACTATTGGCAACGAG-3'; and {beta}-actin antisense, 5'-CCTGTCAGCAATGCCTGGTACAT-3', which yield products of 322 and 197 bp, respectively.

For the generation of standard curves, the corresponding cDNA were cloned into pGEM4Z (Promega, Southampton, U.K.). The concentration of DNA plasmid stock was determined by the OD at 260 nm. Copy number for each plasmid was calculated on the spectrophotometric reading. The linear range of the assay was determined by the amplification of log serial dilutions of plasmids from 500 to 5 x 106. The progress of the PCR amplification was monitored by real-time fluorescence emitted from SYBR Green during the extension time. The cycles were 95°C for 3 min, followed by 40 cycles of 95°C for 20 s, 59°C for 20 s, and 72°C for 20 s. At the end of each PCR run, a melt curve analysis was performed to show the absence of nonspecific bands. The sizes of products were confirmed by agarose gel electrophoresis.

For each sample, SOCS-3 mRNA levels were expressed as relative copy number normalized against {beta}-actin mRNA. This was achieved by constructing a standard curve for each PCR run from serial dilutions of purified plasmid DNA with specified amplicon. The mRNA copy number was calculated for each sample from the standard curves by the instrument’s software. Samples were analyzed in triplicate. For each sample SOCS-3 copy number relative to 106 {beta}-actin copies in the same sample was calculated. Results were then expressed as a percentage of the M-CSF-treated control value (SOCS-3 copy number per 106 {beta}-actin of M-CSF control: A, 7.55 x 102; B, 1.51 x 103; C, 6.42 x 102). Results are the mean of two separate experiments, each consisting of three samples ± SEM.

SOCS-3-expressing retroviral vector

SOCS-3 was transduced using a retroviral vector, pBabe puro, which expresses cDNA inserts constitutively under the control of a retroviral enhancer-promoter (32). The coding region of mouse SOCS-3 (760 bp) was PCR amplified from pEF-FLAG-I/mSOCS-3 (31) with a 5' primer containing a BamHI site and a Kozak sequence and with a 3' primer containing a SalI site, and cloned into pBabe puro. The resulting plasmid pBabe-SOCS-3 was sequenced (Cambridge Biolabs, Cambridge, U.K.) to confirm the SOCS-3 sequence. The pBabe-SOCS-3 and pBabe-empty (control) vectors were then transfected into the Phoenix retroviral packaging cell line (28) using FuGENE-6 (Roche, Indianapolis, IN). After 48 h, stably transfected cells were selected by replacing growth medium with fresh medium containing puromycin (2.5 µg/ml). After a further 48-h period, cells were washed twice, and fresh puromycin containing medium was added. Stably transfected clones were picked 4–7 days later and grown to confluence in 25-cm2 flasks. Clones producing high viral titers were identified by infecting NIH-3T3 cells with viral supernatant for 16 h. After incubation in fresh medium for an additional 2 days, stably infected colonies were selected with puromycin (2.5 µg/ml) for 2 days, and viral titer was calculated: puro CFU/ml = number of puro-resistant colonies/virus volume. Supernatants of the retrovirus producing cells showed a similar viral titer against NIH-3T3 cells (pBabe-SOCS-3 4.9 x 106 CFU/ml; pBabe-empty 4.1 x 106 CFU/ml).

Infection of M-CSF-dependent precursors with control and SOCS-3-expressing retroviruses

Nonadherent, M-CSF-dependent bone marrow cells (106 cells/ml) were added to the wells of 96-well plates containing Thermanox coverslips (Nunc, Naperville, IL) or bone slices and cultured in M-CSF (10 ng/ml) for 48 h. Medium was then removed and replaced with supernatant of pBabe-SOCS-3 or pBabe-empty virus-producing Phoenix cells together with 8 µg/ml polybrene and M-CSF (10 ng/ml). The cells were then centrifuged at 800 rpm to increase infection efficiency and were incubated for 16 h at 37°C. Viral supernatant was removed and replaced with EMEM containing M-CSF (30 ng/ml) and RANKL (30 ng/ml). After incubation for an additional 2 days, stably infected cells were selected by addition of puromycin (2.5 µg/ml) for 3 days. Control cultures to which virus had not been added showed no viable cells. Infection rates for both retroviruses were similar (pBabe-SOCS-3, 55–70%; pBabe-empty, 60–70%). Puromycin was then removed, and coverslips and bone slices were assessed 3–7 days later for osteoclast formation and bone resorption as described below.

SOCS-3 antisense studies

The effect of SOCS-3 knockdown on osteoclast formation was examined using a phosphorothioate antisense oligonucleotide (ODN) (5'-TCA CTC TGC AGC GAA AAG-3') specifically targeting nt 320–337 of mouse SOCS-3 mRNA manufactured by Biognostik (Gottingen, Germany; Biognostik is the owner of the intellectual property rights of the antisense sequence). The control ODN is the reverse complement of the target sequence and contains no cross-homology to other sequences on the GenBank database. M-CSF-dependent mononuclear cells were incubated with M-CSF (30 ng/ml), RANKL (30 ng/ml), and FuGENE6 (0.003%, v/v) with or without TGF-{beta}1 (0.1 ng/ml) in the presence of antisense SOCS-3 ODN (2 µM) or control ODN (2 µM) for 6 days. Cells were fixed and stained for tartrate resistant acid phosphatase (TRAP).

Assessment of the effect of TGF-{beta} on inhibition of osteoclast formation by IFN-{beta}

Nonadherent, M-CSF-dependent bone marrow cells were incubated in 96-well-plates (105 cells/ml) for 6 days with M-CSF (30 ng/ml) and RANKL (30 ng/ml) with or without IFN-{beta} (5 U/ml) and TGF-{beta}1 (0.1 ng/ml). Cultures were fixed and assessed for osteoclast formation.

TRAP cytochemistry

Osteoclast formation on coverslips and bone slices was evaluated by quantification of TRAP-positive multinuclear cells (MNC) containing three or more nuclei. After incubation, cells on coverslips or bone slices were washed, fixed in 10% formalin for 10 min, permeabilized in acetone for 10 min, washed, and stained for acid phosphatase in the presence of 0.05 mol/liter sodium tartrate, using napthol AS-BI phosphate as a substrate (33). Cells were counterstained with hematoxylin.

Assessment of bone resorption

Resorption was quantified on bone slices after TRAP staining. For this, cells were removed from the bone surface by immersion in 10% NaOCl (BDH, Poole, U.K.) for 10 min, followed by washing in water. After drying, bone slices were mounted on glass slides and sputter-coated with gold. Resorption was quantified by reflected light microscopy using an eyepiece graticule.

Statistical analysis

Differences between groups were assessed using ANOVA (StatView version 5.01; Abacus Concepts, Berkley, CA). A difference of p < 0.05 was considered significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Osteoclasts express SOCS-3 mRNA

To assess the pattern of SOCS expression in macrophages and osteoclasts we performed Northern analysis on total RNA extracted from bone marrow precursors incubated in the presence of M-CSF with or without RANKL and TGF-{beta} for 5 days. While the expression of SOCS1, -2, or -3 or CIS mRNA was not detectable in M-CSF-treated bone marrow macrophages, SOCS-3 mRNA expression was detected in RANKL-induced osteoclasts as previously reported (34) and was further up-regulated in osteoclasts formed in the presence of TGF-{beta} (Fig. 1). Furthermore, mononuclear phagocyte precursors incubated with TGF-{beta} for 5 days also expressed SOCS-3 mRNA (Fig. 1). The expression of SOCS-1, SOCS-2, or CIS mRNA was not detected in osteoclasts incubated in RANKL or TGF-{beta} (data not shown).



View larger version (49K):
[in this window]
[in a new window]
  		FIGURE 1. Effect of TGF-{beta} on SOCS-3 mRNA expression. Total RNA was prepared from M-CSF-dependent bone marrow precursors incubated (3 x 104/ml) for 5 days with M-CSF (30 ng/ml) and combinations of TGF-{beta}1 (0.1 ng/ml) and RANKL (30 ng/ml). For Northern blot analysis, 15 µg of total RNA was separated on a 1.2% agarose-formaldehyde gel, transferred to a Hybond-N membrane, and hybridized with specific 32P-labeled cDNA probes for murine SOCS-3 or {beta}-actin prepared by the random primer method. After hybridization, the membrane was washed (2x SSPE and 0.1% SDS, twice for 15 min each time; 1x SSPE and 0.1% SDS, 30 min; 0.5x SSPE and 0.1% SDS, twice for 15 min each time; all at 42°C) and autoradiographed using Hyperfilm.

 
To determine the kinetics and magnitude of TGF-{beta}-induced SOCS-3 expression in mononuclear-phagocyte precursors we further examined TGF-{beta}-induced SOCS-3 expression in noncommitted precursors using quantitative RT-PCR. TGF-{beta} induced a >3-fold increase in SOCS-3 mRNA expression in noncommitted precursors within 1 h (Fig. 2). Consistent with the sustained expression of SOCS-3 mRNA in precursors incubated in TGF-{beta} for 5 days, SOCS-3 mRNA expression remained 4-fold greater than that of controls 24 h after the addition of TGF-{beta}. Thus, TGF-{beta} induces a rapid and sustained elevation in SOCS-3 mRNA expression in noncommitted precursors and mature osteoclasts. RANKL itself induced an approximate doubling of mRNA levels of SOCS-3 (Fig. 2). In cultures to which both RANKL and TGF-{beta} were added, there was a sustained increase in the level of SOCS-3 mRNA, to ~7 times control levels (Fig. 2).



View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 2. Quantitative RT-PCR analysis of TGF-{beta}-induced SOCS-3 mRNA expression in mononuclear precursors. Nonadherent, M-CSF-dependent bone marrow cells (3 x 104/ml) were incubated for 2 days in M-CSF (10 ng/ml). Cultures were then treated with TGF-{beta}1 (0.1 ng/ml; A), RANKL (30 ng/ml; B), or TGF-{beta}1 (0.1 ng/ml; C) and RANKL (30 ng/ml) for 1–24 h, and total RNA was extracted. For assessment of RNA expression, 2 µg of total RNA was reverse transcribed for 1 h at 42°C. Real-time PCR was conducted with the I-Cycler using the DNA-binding dye SYBR Green and specific primers for murine SOCS-3 or {beta}-actin for the detection of PCR products. For the generation of standard curves, the corresponding cDNA were cloned into pGEM4Z (SOCS-3 pGEM4Z or {beta}-actin pGEM4Z). The progress of the PCR amplification was monitored by real-time fluorescence emitted from SYBR Green during the extension time. The cycles were 95°C for 3 min, followed by 40 cycles of 95°C for 20 s, 59°C for 20 s, and 72°C for 20 s. For each sample, SOCS-3 mRNA levels were expressed as the relative copy number normalized against {beta}-actin mRNA. This was achieved by constructing a standard curve for each PCR run from serial dilutions of purified plasmid DNA with specified amplicon. The mRNA copy number was calculated for each sample from the standard curves by the instrument’s software. Samples were analyzed in triplicate. For each sample SOCS-3 copy number relative to 106 {beta}-actin copies in the same sample was calculated. Results were then expressed as a percentage of the M-CSF-treated control (SOCS-3 copy number per 106 {beta}-actin of M-CSF control: A, 7.55 x 102; B, 1.51 x 103; C, 6.42 x 102). Results are the mean of two separate experiments each consisting of three samples ± SEM.

 
Retroviral-mediated SOCS-3 expression enhances osteoclast differentiation, but not activation

SOCS-3 is a STAT-induced negative feedback regulator of the JAK/STAT signaling pathway. Interestingly, previous studies suggest that SOCS-3 expression may mediate antagonistic interactions between inflammatory signaling pathways. SOCS-3 expression inhibits the anti-viral effect of IFN-{gamma}, and the suppression of IFN-{gamma} signaling in response to IL-10 is also attributed to SOCS-3 expression (35, 36).

The rapid and sustained expression of SOCS-3 mRNA in response to TGF-{beta} raises the possibility that SOCS-3 expression may form part of the mechanism by which TGF-{beta} determines the fate of noncommitted precursors, preventing inhibitory JAK/STAT signals and thereby facilitating osteoclast formation. Therefore, to examine the role of SOCS-3 in lineage switching in mononuclear phagocyte precursors we used a pBabe retroviral vector system to express SOCS-3 in noncommitted precursors. Similar to previous findings, when nonadherent, M-CSF-dependent mononuclear phagocyte precursors infected with empty control virus (pBabe-empty) were incubated with RANKL, strongly TRAP-positive MNCs formed within 8 days (Fig. 3).



View larger version (88K):
[in this window]
[in a new window]
  		FIGURE 3. SOCS-3 expression enhances RANKL-induced osteoclast formation. Nonadherent M-CSF-dependent bone marrow cells (106/ml) were incubated on plastic coverslips in 96-well plates with M-CSF (10 ng/ml) for 2 days. Cells were then infected with pBabe-SOCS-3 or pBabe-empty (control) retroviruses. Cultures were incubated with M-CSF (30 ng/ml) and RANKL (30 ng/ml) for 8–14. days. Infected cells were selected with puromycin (2.5 µg/ml) between days 2 and 5. Coverslips were fixed and stained for TRAP, and total cell number and the number of TRAP-positive MNC were counted (A). Values are the mean ± SEM of three separate experiments (n = 24). *, p < 0.05 vs control cultures. B and C, Photomicrographs of cultures after incubation as described above with pBabe (empty retrovirus; B) and SOCS-3-expressing retrovirus (C).

 
Interestingly, SOCS-3 expression caused a substantial increase in the number of TRAP-positive MNCs that formed in the presence of RANKL compared with cultures infected with pBabe-empty at all time points examined (Fig. 3). This increase in MNC number was not attributable to differences in infection rate or total cell number, as cell numbers in SOCS-3- and pBabe-empty-infected cultures did not differ at any time point examined (Table I). Elevated SOCS-3 mRNA levels were confirmed in pBabe-SOCS-3-infected precursors by real-time PCR (pBabe SOCS-3-infected cells, 4.92 x 105 SOCS-3 mRNA copies/1 x 106 {beta}-actin; TGF-{beta}-treated pBabe-control-infected cells, 2.60 x 103 SOCS-3 copies/1 x 106 {beta}-actin).


View this table:
[in this window]
[in a new window]
  		Table I. Total cell numbers in pBabe-infected and SOCS 3-infected precursors incubated with M-CSF and RANKL

 
Similarly, SOCS-3-infected precursors incubated on bone slices showed a significant, but smaller, increase in TRAP-positive MNC cell numbers compared with controls (Fig. 4). This was accompanied by an increase in the extent of bone resorption in SOCS-3-infected cultures. The increase in the number of MNC by SOCS-3 correlates with the increase in bone resorption. This is consistent with the action of TGF-{beta} to increase the number of TRAP-positive MNCs formed by RANKL, but to have no effect on the resorption of each osteoclast so formed (4). The relatively minor increase in TRAP-positive MNCs induced by SOCS-3 virus on bone compared with plastic is also consistent with the only minor enhancement of osteoclast differentiation achieved by TGF-{beta} in precursors on bone slices compared with precursors on plastic (4), which was attributable to the presence of TGF-{beta} in bone matrix.



View larger version (57K):
[in this window]
[in a new window]
  		FIGURE 4. Effect of SOCS-3 expression on osteoclast differentiation and activation on bone. Nonadherent, M-CSF-dependent bone marrow cells were incubated on slices of bovine cortical bone with M-CSF (10 ng/ml) for 2 days. Cells were then infected with pBabe-SOCS-3 or pBabe-empty (control) retroviruses. Cultures were incubated with M-CSF (30 ng/ml) and RANKL (30 ng/ml) for 8 days. A, Bone slices were fixed, and the number of TRAP-positive MNC was quantified. B, The percentage of bone surface resorbed. Following assessment of TRAP-positive MNC the bone slices were immersed in NaOCl and sputter-coated with gold, and the extent of resorption was quantified. Values are expressed as the mean ± SEM of three separate experiments (n = 24). *, p < 0.05 vs control. C and D, Photomicrograph of bone surface after removal of cells after incubation of nonadherent bone marrow cells with M-CSF (30 ng/ml) plus RANKL (30 ng/ml) as described above and infected with either pBabe-empty (C) or pBabe-SOCS-3 (D).

 
RANKL-induced osteoclast formation is abolished by anti-TGF-{beta} Abs, suggesting that osteoclasts induced by RANKL without the addition of exogenous TGF-{beta} are dependent on TGF-{beta} present in the culture medium or produced by the precursors themselves (4). Therefore, to further determine the possible role of SOCS-3 expression in osteoclast formation we examined the ability of SOCS-3 expression to restore osteoclast differentiation in the presence of pan-specific TGF-{beta} Ab. Similar to previous studies, RANKL-induced osteoclast formation was significantly suppressed in control pBabe-empty-infected cells incubated with pan-specific TGF-{beta} Ab (Fig. 5) (4). On the other hand, in SOCS-3-infected precursors RANKL-induced osteoclast formation was not significantly suppressed by pan-specific TGF-{beta} Ab (Fig. 5). This indicates that SOCS-3 enables RANKL-induced osteoclast differentiation in the absence of TGF-{beta}. Similarly, addition of TGF-{beta} to control pBabe-empty-infected precursors significantly enhanced osteoclast differentiation, whereas it had no significant effect on osteoclast formation in SOCS-3-infected precursors (Fig. 5).



View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 5. SOCS-3 expression opposes the inhibitory effect of pan-specific TGF-{beta} Abs. Nonadherent, M-CSF-dependent bone marrow cells were incubated in M-CSF (10 ng/ml) for 2 days. Cells were then infected with pBabe-SOCS-3 or pBabe-empty retroviruses. A, Cultures were incubated with M-CSF (30 ng/ml) and RANKL (100 ng/ml) with or without pan-specific TGF-{beta} Ab (20 µg/ml) for 6 days. Coverslips were fixed, and the total cell number and the number of TRAP-positive MNC cells were counted. Values are the mean ± SEM of two separate experiments (n = 16). *, p < 0.05 vs all other groups; **, p < 0.05 vs pBabe MR. There was no significant difference in the number of TRAP-positive MNC cells formed in SOCS-3-infected cells incubated in M-CSF and RANKL vs SOCS-3-infected cells incubated with M-CSF, RANKL, and pan-specific TGF-{beta} Ab. B, Cultures were incubated with M-CSF (30 ng/ml) and RANKL (100 ng/ml) with or without TGF-{beta} (0.1 ng/ml) for 6 days. Coverslips were fixed, and the total cell number and the number of TRAP-positive MNC cells were counted. Values are the mean ± SEM of two separate experiments (n = 14). *, p < 0.05 vs all other groups. There was no significant difference in the number of TRAP-positive MNC cells formed in SOCS-3-infected cells incubated with or without TGF-{beta}.

 
SOCS-3 antisense ODN suppress RANKL-induced osteoclast formation and the enhancing effect of TGF-{beta}

The ability of SOCS-3 retroviruses to enhance RANKL-induced osteoclast formation and suppress the inhibitory effect of TGF-{beta} Abs strongly suggests that SOCS-3 has a role in the mechanism by which TGF-{beta} enables osteoclast formation. To further test the role of SOCS-3 in the enhancement of osteoclast formation by TGF-{beta} we examined the effect of knocking down SOCS-3 using a specific SOCS-3 antisense oligonucleotide. RANKL-induced osteoclast formation was markedly suppressed in cultures incubated with SOCS-3 antisense ODN compared with cultures incubated with control ODN (Fig. 6). In addition, SOCS-3 antisense ODN strongly reduced the enhancing effect of exogenously administered TGF-{beta} (Fig. 6) compared with control cultures.



View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 6. Antisense SOCS-3 oligonucleotides suppress osteoclast formation and blunt the enhancing effect of TGF-{beta}. Nonadherent, M-CSF-dependent bone marrow precursors were incubated for 6 days with combinations of M-CSF (30 ng/ml), RANKL (30 ng/ml), TGF-{beta}1 (0.1 ng/ml), and either antisense SOCS-3 ODN (2 µM) or control ODN (2 µM). Cells were fixed, and the number of TRAP-positive MNC was quantified. Values are expressed as the mean ± SEM of two separate experiments (n = 12). There was no significant difference between antisense SOCS-3 ODN cultures incubated with or without TGF-{beta}. *, Significantly different vs all other groups (p < 0.05).

 
TGF-{beta} suppresses the antiosteoclastic action of IFN-{beta}

The culture environment potentially contains inflammatory stimuli that may act to prime precursors for roles alternative to bone resorption. One such factor is IFN-{beta}, which has recently been shown to function as an autocrine regulator of osteoclast differentiation, limiting RANKL-induced osteoclast formation. In the studies by Takayangi et al. (14), RANKL was shown to induce IFN-{beta} expression in osteoclast precursors, which, in turn, suppressed subsequent RANKL-induced osteoclast formation. However, while TGF-{beta} has been shown to antagonize inflammatory stimuli (16), it is not known whether TGF-{beta} prevents the inhibitory effect of IFN-{beta} on osteoclast formation. Therefore, we assessed the ability of TGF-{beta} to override the suppressive action of IFN-{beta} on osteoclast formation. As expected, addition of IFN-{beta} to bipotential osteoclast precursors significantly inhibited RANKL-induced TRAP-positive MNC formation (Fig. 7). Interestingly, osteoclast formation in cultures treated with both TGF-{beta} and IFN-{beta} was significantly greater than that of controls (Fig. 7), indicating that TGF-{beta} prevents the suppressive action of IFN-{beta}.



View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 7. TGF-{beta} opposes the inhibitory effect of IFN-{beta} on osteoclast formation. Nonadherent, M-CSF-dependent bone marrow precursors were incubated for 6 days with M-CSF (30 ng/ml) and RANKL (30 ng/ml) with or without IFN-{beta} (5 U/ml) and/or TGF-{beta}1 (0.1 ng/ml). Cells were fixed, and the number of TRAP-positive MNC was quantified. Values are expressed as the mean ± SEM of two separate experiments (n = 16). *, p < 0.01 vs control.

 
SOCS-3 expression enables osteoclast formation in the presence of IFN-{beta}

IFN-{beta}, upon binding to its receptor, activates JAK1 and Tyk2, which, in turn, phosphorylates STAT1 and STAT2, which form part of the IFN-stimulated gene factor-3 signaling complex that is responsible for controlling the transcription of target genes (19, 37). One regulatory factor activated by IFN-{beta} is SOCS-3 (38), which inhibits signaling by binding to the kinase activation loop of receptor-associated JAKs, which, in turn, prevents further STAT activation and STAT-dependent transcription (25, 39). Therefore, to examine whether SOCS-3 expression could account for the suppressive effect of TGF-{beta} on IFN-{beta} signaling we examined the effect of IFN-{beta} on osteoclast formation in precursors expressing pBabe-SOCS-3 retrovirus. Similar to the results described above, SOCS-3 significantly increased RANKL-induced osteoclast differentiation compared with that in control cultures (Fig. 8). Moreover, while IFN-{beta} abolished TRAP-positive MNC production in control cultures, it had no significant effect on RANKL-induced osteoclast formation in cultures of SOCS-3-expressing precursors (Fig. 8). Thus, SOCS-3 expression opposes the inhibitory effect of IFN-{beta} on osteoclast formation, maintaining the ability of precursors to form osteoclasts. These data raise the possibility that TGF-{beta}-induced SOCS-3 expression in bipotential precursors prevents inhibitory JAK/STAT signals, thus acting to prime precursors for a role in bone resorption rather than other macrophage functions.



View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 8. SOCS-3 expression enables the formation of osteoclasts in the presence of IFN-{beta}. Nonadherent, M-CSF-dependent bone marrow cells were incubated in M-CSF (10 ng/ml) for 2 days. Cells were then infected with pBabe-SOCS-3 or pBabe-empty retroviruses. Cultures were incubated with M-CSF (30 ng/ml) and RANKL (30 ng/ml) with or without IFN-{beta} (5 U/ml) for 6 days. Coverslips were fixed, and the total cell number and the number of TRAP-positive MNC were counted. Values are the mean ± SEM of two separate experiments (n = 16). *, p < 0.05 vs all other groups; **, p < 0.05 vs pBabe M-CSF and RANKL. There was no significant difference in the number of TRAP-positive MNC formed in SOCS-3-infected cells incubated with or without IFN-{beta}.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
TGF-{beta} has a crucial role in determining lineage switching in immature mononuclear phagocytes, acting to maintain and enhance the responsiveness of osteoclast precursors to RANKL (4, 9). In the absence of exogenous TGF-{beta}, only a proportion of precursors form osteoclasts. This may be due to the presence of cytokines such as IFN-{beta} in the tissue culture environment, which direct the differentiation of precursors toward inflammatory and cytocidal macrophagic pathways rather than the osteoclastic lineage (14). IFN-{beta}, like many other factors that suppress osteoclast formation (13, 17, 18), signal through the JAK/STAT pathway (19, 20). JAK/STAT activation may therefore represent a central mechanism by which inhibitory cytokines suppress osteoclast formation.

Following cytokine activation, JAK/STAT signaling is modulated by the expression of a number of STAT-induced SOCS isoforms. SOCS expression mediates the antagonistic action of several factors on STAT activation. In the present study we demonstrate that TGF-{beta} rapidly induces sustained expression of SOCS-3 mRNA in bipotential osteoclast-macrophage precursors. Like TGF-{beta}, SOCS-3 expression in mononuclear precursors significantly augmented RANKL-induced osteoclast differentiation and prevented the suppressive action of IFN-{beta} on osteoclast formation. Furthermore, SOCS-3 antisense oligonucleotides suppressed RANKL-induced osteoclast formation and the enhancing effect of exogenously administered TGF-{beta}. These data suggest that TGF-{beta} may act to facilitate osteoclast formation through the induction of SOCS-3, thereby inhibiting JAK/STAT signaling and facilitating the differentiation of noncommitted precursors to the osteoclastic lineage rather than to alternative, inflammatory macrophage pathways.

Macrophage fate is determined by a relatively short incubation in cytokine, as IFN-{beta} rapidly activates transcription of targets genes in noncommitted precursors (40). Thus, a candidate for mediating the suppressive action of TGF-{beta} would have to be up-regulated and prevent macrophage differentiation within this initial period. SOCS rapidly block the phosphorylation of STATs by inhibiting the kinase activity of JAKs. The mechanism by which SOCS-3 inhibits signaling differs from that of other SOCS isoforms. Unlike SOCS-1, SOCS-3 does not directly inhibit JAK2 activity, the ability of SOCS-3 to inhibit growth hormone-induced JAK2 activation increases significantly in the presence of the growth hormone receptor (41), indicating that SOCS-3 indirectly inhibits STAT phosphorylation through an association with the cytokine receptor (42). SOCS-3 may also suppress signaling by increasing STAT degradation. SOCS box-containing proteins recruit activated signaling proteins to the proteasome (43) through an association of the SOCS box with elongins B and C (43, 44), facilitating the ubiquitination and subsequent degradation of the signaling protein. Therefore, in view of the rapid nature by which SOCS-3 inhibits STAT activation, it seems likely that induction of SOCS-3 mRNA within 1 h would be sufficient to suppress the differentiation of precursors toward other macrophagic lineages.

The precise stage of maturation when lineage switching in mononuclear phagocyte precursors occurs is not known. It is likely that it is determined within the first few days of culture, since bone marrow cells become increasingly resistant to osteoclast induction as the culture period progresses (3, 4, 5). TGF-{beta} prevents this resistance from developing; the proportion of cells in bone marrow cultures that form osteoclasts is the same in cultures preincubated in TGF-{beta} and those in which RANKL is present from the start (4). The ability of TGF-{beta} to maintain precursors in a RANKL-responsive state for several days may be explained by its ability to maintain a level of SOCS-3 expression sufficient to continuously suppress signals from proinflammatory stimuli generated by macrophages in vitro and by the culture environment, which is itself proinflammatory and capable of macrophage activation (10, 11, 12).

SOCS-3 may inhibit signaling by other osteoclast inhibitory factors in addition to IFN-{beta}. Several studies have implicated SOCS-3 in the suppression of IFN-{gamma} signaling. SOCS-3 expression inhibits the antiviral effect of IFN-{gamma} in macrophages, and the suppression of IFN-{gamma} signaling in response to IL-10 is also attributable to an up-regulation of SOCS-3 expression (35, 36, 38). The attenuation of IFN-{gamma} signaling by SOCS-3 in these studies is attributed to a reduction in STAT1 phosphorylation (35). Thus, other cytokines that phosphorylate STAT1 may also be inhibited by TGF-{beta}-induced SOCS-3 expression. In addition, SOCS-3 has been shown to prevent the phosphorylation of STAT3 (45), which is activated in the IL-10 and IL-4 signaling cascades, both of which have been shown to suppress osteoclast differentiation (21, 46, 47).

The ability of TGF-{beta} to induce SOCS-3 expression within 1 h suggests that this is mediated by a direct effect of TGF-{beta}-activated intracellular signals on SOCS-3 transcription, since this is too short a time for the transcription and expression of an intermediary factor. Binding of TGF-{beta} to its receptor complex induces the phosphorylation of S mothers against decapentaplegic (SMADs) (48), which bind to DNA and associate with numerous transcription factors. TGF-{beta} also activates mitogen-activated protein kinases (49, 50) through its ability to stimulate TAK1 (TGF-{beta}-activated kinase) (51, 52). The relative importance of mitogen-activated protein kinase and SMAD signaling pathways in TGF-{beta}-induced SOCS-3 expression and osteoclast formation is not known.

The ability of SOCS-3 expression to enhance osteoclast formation and of antisense SOCS-3 to significantly blunt the enhancing effect of TGF-{beta} does not preclude the involvement of additional mechanisms by which TGF-{beta} enables osteoclast formation. It is possible that TGF-{beta} may induce the expression of additional, novel SOCS isoforms to switch off JAK/STAT signaling by other inhibitory factors. Alternatively, other mechanisms may be involved in the suppression of inhibitory signals. TGF-{beta} has been shown to modulate the signaling response of other cytokines by competing for the transcriptional coactivator CRE binding protein/p300. In fibroblasts the antagonistic regulation of type I collagen expression by TGF-{beta} and IFN-{gamma} is attributed to a competition between activated SMAD and STAT complexes for limited amounts of CRE binding protein/p300 (53). On the other hand, TGF-{beta} may act to potentiate RANKL-induced signaling cascade through its ability to activate TAK1. Recently, TAK1 has been suggested to form part of a transcriptional complex that has a central role in the RANKL signaling pathway (54). RANKL stimulates the formation of a complex containing RANK, TNFR-associated factor 6, TAK1 binding protein 2, and TAK1, leading to the activation of NF-{kappa}B (55, 56). Therefore, TGF-{beta} may facilitate the formation of this complex through the activation of TAK1 and the subsequent increase in NF-{kappa}B activity, which is a key component in the signaling cascade leading to osteoclast formation.

Whatever the roles of alternative mechanisms, this study provides a possible mechanistic basis for the regulation of macrophage-osteoclast lineage regulation and also has important implications for the mechanism by which TGF-{beta} modulates macrophage activation by inflammatory cytokines. Our data show that TGF-{beta} rapidly induces SOCS-3 mRNA expression in immature mononuclear phagocytes. Like TGF-{beta}, SOCS-3 expression in precursors significantly enhances RANKL-induced osteoclast formation and opposes the inhibitory effect of IFN-{beta} on osteoclast formation. SOCS-3 expression also opposes the inhibitory effect of anti-TGF-{beta} Ab on osteoclast differentiation. Furthermore, SOCS-3 antisense oligonucleotide suppresses RANKL-induced osteoclast formation and significantly blunts the enhancing effect of TGF-{beta}. This suggests that TGF-{beta}-induced SOCS-3 expression in osteoclast precursors may assist the commitment to the osteoclastic lineage by suppressing exogenous and endogenous proinflammatory, antiosteoclastic JAK/STAT signals, thus acting to prime precursors for a role in bone resorption rather than cytocidal and inflammatory functions (Fig. 9).



View larger version (42K):
[in this window]
[in a new window]
  		FIGURE 9. TGF-{beta} facilitates osteoclast formation by preventing the inhibitory effect of IFN-{beta} on the RANKL signaling cascade. TGF-{beta} induces SOCS-3 expression in noncommitted mononuclear phagocyte precursors, which, in turn, inhibits subsequent signaling through the JAK/STAT pathway. It has been shown that RANKL induces the production of IFN-{beta} in precursors, and that IFN-{beta} suppresses osteoclastic differentiation via JAK-STAT-mediated suppression of Fos (12 ).

 
Osteoclast differentiation depends on TGF-{beta}, and the presence of very large amounts of this cytokine in bone matrix might contribute to an explanation for the regular differentiation of osteoclasts only in bone despite exposure of macrophagic precursors to osteoclast-inductive cytokines in other tissues.


   Acknowledgments
 
We are grateful to Ray Moss (Medical Imaging Facility, St. George’s Hospital Medical School) and Valerie Emmons for assistance in the preparation of text and figures.


   Footnotes
 
1 This work was supported by the Wellcome Trust, the Arthritis Research Campaign, and National Institutes of Health Grant ROIGM60533. Back

2 Address correspondence and reprint requests to Dr. Simon W. Fox, Department of Cellular Pathology, St. George’s Hospital Medical School, Cranmer Terrace, Tooting, London, U.K. SW17 0RE. E-mail: swfox{at}sghms.ac.uk Back

3 Abbreviations used in this paper: RANKL, receptor activator of NF-{kappa}B ligand; CIS, cytokine-inducible gene; EMEM, MEM with Earle’s salts; JAK, Janus kinase; MNC, multinuclear cell; ODN, oligonucleotide; SMAD, S mothers against decapentaplegic; SOCS, suppressor of cytokine signaling; SSPE, sodium chloride sodium phosphate EDTA; TAK1, TGF-{beta}-activated kinase 1; TRAP, tartrate-resistant acid phosphatase. Back

Received for publication September 12, 2002. Accepted for publication January 31, 2003.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Suda, T., N. Takahashi, N. Udagawa, E. Jimi, M. T. Gillespie, T. J. Martin. 1999. Modulation of osteoclast differentiation and function by the new member of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20:345.[Abstract/Free Full Text]
  2. Chambers, T. J.. 2000. Regulation of the differentiation and function of osteoclasts. J. Pathol. 192:4.[Medline]
  3. Wani, M. R., K. Fuller, N. S. Kim, Y. Choi, T. Chambers. 1999. Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. Endocrinology 140:1927.[Abstract/Free Full Text]
  4. Fuller, K., J. M. Lean, K. E. Bayley, M. R. Wani, T. J. Chambers. 2000. A role for TGF-{beta}1 in osteoclast differentiation and survival. J. Cell Sci. 113:2445.[Abstract]
  5. Arai, F., T. Miyamoto, O. Ohneda, T. Inada, T. Sudo, K. Brasel, T. Miyata, D. M. Anderson, T. Suda. 1999. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor {kappa}B (RANK) receptors. J. Exp. Med. 190:1741.[Abstract/Free Full Text]
  6. Smith, C. A., T. Farrah, R. G. Goodwin. 1994. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76:959.[Medline]
  7. Itoh, K., N. Udagawa, T. Katagiri, S. Iemura, N. Ueno, H. Yasuda, K. Higashio, J. M. W. Quinn, M. T. Gillespie, T. J. Martin, et al 2001. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-{kappa}B ligand. Endocrinology 142:3656.[Abstract/Free Full Text]
  8. Koseki, T., Y. Gao, N. Okahashi, Y. Murase, T. Tsujisawa, T. Sato, K. Yamato, T. Nishihara, T. . 2002. Role of TGF-{beta} family in osteoclastogenesis induced by RANKL. Cell. Signalling 14:31.[Medline]
  9. Kaneda, T., T. Nojima, M. Nakagawa, A. Ogasawara, H. Kaneko, T. Sato, H. Mano, M. Kumegawa, Y. Hakeda. 2000. Endogenous production of TGF-{beta} is essential for osteoclastogenesis induced by a combination of receptor activator of NF-{kappa}B ligand and macrophage-colony-stimulating factor. J. Immunol. 165:4254.[Abstract/Free Full Text]
  10. Friedman, S. L., G. Yamasaki, L. Wong. 1994. Modulation of transforming growth factor {beta} receptors of rat lipocytes during the hepatic wound healing response: enhanced binding and reduced gene expression accompany cellular activation in culture and in vivo. J. Biol. Chem. 269:10551.[Abstract/Free Full Text]
  11. Iyer, V. R., M. B. Eisen, D. T. Rosse, G. Schuler, T. Moore, J. C. F. Lee, J. M. Trent, L. M. Staudt, J. Hudson, Jr., M. S. Boguski, et al 1999. The transcriptional program in the response of human fibroblasts to serum. Science 283:83.[Abstract/Free Full Text]
  12. Thyberg, J.. 1996. Differentiated properties and proliferation of arterial smooth muscle cells in culture. Int. Rev. Cytol. 169:183.[Medline]
  13. Lacey, D. L., J. M. Erdmann, S. L. Teitelbaum, H.- L. Tan, J. Ohara, A. Shioi. 1995. Interleukin 4, interferon-{gamma}, and prostaglandin E impact the osteoclast cell-forming potential of murine bone marrow macrophages. Endocrinology 136:2367.[Abstract]
  14. Takayanagi, H., S. Kim, K. Matsuo, H. Suzuki, T. Suzuki, K. Sato, T. Yokochi, H. Oda, K. Nakamura, N. Ida, et al 2002. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-{beta}. Nature 416:744.[Medline]
  15. Fox, S. W., T. J. Chambers. 2000. Interferon-{gamma} directly inhibits TRANCE-induced osteoclastogenesis. Biochem. Biophys. Res. Commun. 276:868.[Medline]
  16. Fox, S. W., K. Fuller, K. E. Bayley, J. M. Lean, T. J. Chambers. 2000. TGF-{beta}1 and IFN-{gamma} direct macrophage activation by TNF-{alpha} to osteoclastic or cytocidal phenotype. J. Immunol. 165:4957.[Abstract/Free Full Text]
  17. Novak, U., A. G. Harpur, L. Paradiso, V. Kanagasundaram, A. Jaworowski, A. F. Wilks, J. A. Hamilton. 1995. Colony-stimulating factor 1-induced STAT1 and STAT3 activation is accompanied by phosphorylation of Tyk2 in macrophages and Tyk2 and JAK1 in fibroblasts. Blood 86:2948.[Abstract/Free Full Text]
  18. Mui, A. L., H. Wakao, A. M. O’Farrell, N. Harada, A. Miyajima. 1995. Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO J. 14:1166.[Medline]
  19. Stark, G. R., I. M. Kerr, B. R. Williams, R. H. Silverman, R. D. Schreiber. 1998. How cells respond to interferons. Annu. Rev. Biochem. 67:227.[Medline]
  20. Schindler, C., J. E. Darnell. 1995. Transcriptional responses to polypeptide ligands: the Jak-Stat pathway. Annu. Rev. Biochem. 64:621.[Medline]
  21. Abu-Amer, Y.. 2001. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-{kappa}B. J. Clin. Invest. 107:1375.[Medline]
  22. Starr, R., T. A. Willson, E. M. Viney, L. J. Murray, J. R. Rayner, B. J. Jenkins, T. J. Gonda, W. S. Alexander, D. Metcalf, N. A. Nicola, et al 1997. A family of cytokine-inducible inhibitors of signalling. Nature 387:917.[Medline]
  23. Endo, T. A., M. Masuhara, M. Yokouchi, R. Suzuki, H. Sakamoto, K. Mitsui, A. Matsumoto, S. Tanimura, M. Ohtsubo, H. Misawa, et al 1997. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387:921.[Medline]
  24. Naka, T., M. Narazaki, M. Hirata, T. Matsumoto, S. Minamoto, A. Aono, N. Nishimoto, T. Kajita, T. Taga, K. Yoshizaki, et al 1997. Structure and function of a new STAT-induced STAT inhibitor. Nature 387:924.[Medline]
  25. Yoshimura, A., T. Ohkubo, T. Kiguchi, N. A. Jenkins, D. J. Gilbert, N. G. Copeland, T. Hara, A. Miyajima. 1995. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 14:2816.[Medline]
  26. Minamoto, S., K. Ikegame, K. Ueno, M. Narazaki, T. Naka, H. Yamamoto, T. Matsumoto, H. Saito, S. Hosoe, T. Kishimoto. 1997. Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3. Biochem. Biophys. Res. Commun. 237:79.[Medline]
  27. Hilton, D. J., R. T. Richardson, W. S. Alexander, E. M. Viney, T. A. Willson, N. S. Spriggs, R. Starr, S. E. Nicholson, D. Metcalf, N. A. Nicola. 1998. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. Sci. USA 95:114.[Abstract/Free Full Text]
  28. Kinsella, T. M., G. P. Nolan. 1996. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum. Gene Ther. 7:1405.[Medline]
  29. Chambers, T. J.. 1985. The pathobiology of the osteoclast. J. Clin. Pathol. 38:241.[Abstract/Free Full Text]
  30. Chomczynski, P., N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium-thiocynate-phenol-chloroform extraction. Anal. Biochem. 162:156.[Medline]
  31. Haque, S. J., P. C. Harbor, B. R. Williams. 2000. Identification of critical residues required for suppressor of cytokine signaling-specific regulation of interleukin-4 signaling. J. Biol. Chem. 275:26500.[Abstract/Free Full Text]
  32. Morgenstern, J. P., H. Land. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:3587.[Abstract/Free Full Text]
  33. Burstone, M. S.. 1958. Histochemical demonstration of acid phosphatases with naphthol AS-phosphate. J. Natl. Cancer Inst. 21:423.
  34. Hayashi, T., T. Kaneda, Y. Toyama, M. Kumegawa, Y. Hakeda. 2002. Regulation of receptor activator of NF-{kappa}B ligand-induced osteoclastogenesis by endogenous interferon-{beta} and suppressors of cytokine signaling (SOCS): the possible counteracting role of SOCSs in IFN-{beta} inhibited osteoclast formation. J. Biol. Chem. 277:27880.[Abstract/Free Full Text]
  35. Ito, S., P. Ansari, M. Sakatsume, H. Dickensheets, N. Vazquez, R. P. Donnelley, A. P. Larner. 1999. Interleukin-10 inhibits expression of both interferon {alpha}- and interferon {gamma}-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 93:1456.[Abstract/Free Full Text]
  36. Song, M. M., K. Shuai. 1998. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J. Biol. Chem. 273:35056.[Abstract/Free Full Text]
  37. Taniguchi, T., K. Ogasawara, A. Takaoka, N. Tanaka. 2001. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 19:623.[Medline]
  38. Crespo, A., M. B. Filla, W. J. Murphy. 2002. Low responsiveness to IFN-{gamma}, after pretreatment of mouse macrophages with lipopolysaccarides, develops via diverse regulatory pathways. Eur. J. Immunol. 32:710.[Medline]
  39. Naka, T., M. Fujimoto, T. Kishimoto. 1999. Negative regulation of cytokine signaling: STAT-induced STAT inhibitor. Trends Biol. Sci. 24:394.
  40. David, M., E. R. Petricoin, C. Benjamin, R. Pine, M. Weber, A. Larner. 1995. Requirement for MAP kinase (ERK2) activity in interferon {alpha}- and interferon {beta}-stimulated gene expression through STAT proteins. Science 269:1721.[Abstract/Free Full Text]
  41. Hansen, J. A., K. Lindberg, D. J. Hilton, J. H. Nielsen, N. Billestrup. 1999. Mechanism of inhibition of growth hormone receptor signaling by suppressor of cytokine signaling proteins. Mol. Endocrinol. 13:1832.[Abstract/Free Full Text]
  42. Cohney, S. J., D. Sanden, N. A. Cacalano. 1999. SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol. Cell. Biol. 19:4980.[Abstract/Free Full Text]
  43. Zhang, J. G., A. Farley, S. E. Nicholson. 1999. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. USA 96:2071.[Abstract/Free Full Text]
  44. Kamura, T., S. Sato, D. Haque. 1998. The elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 12:3782.
  45. Magrangeas, F., O. Boisteau, S. Denis, Y. Jacques, S. Minvielle. 2001. Negative cross-talk between interleukin-11 is mediated by suppressor of cytokine signalling-3 (SOCS-3). Biochem. J. 353:223.[Medline]
  46. Wei, S., M. W. Wang, S. L. Teitelbaum, F. P. Ross. 2002. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-{kappa}B and mitogen-activated protein kinase signaling. J. Biol. Chem. 277:6622.[Abstract/Free Full Text]
  47. Hong, M. H., H. Williams, C. H. Jin, J. W. Pike. 2000. The inhibitory effect of interleukin-10 on mouse osteoclast formation involves novel tyrosine-phosphorylated proteins. J. Bone Miner. Res. 15:911.[Medline]
  48. Miyazono, K., K. Dijke, K. E. Heldin. 2000. TGF-{beta} signalling by Smad proteins. Adv. Immunol. 75:115.[Medline]
  49. Moriguchi, T., N. Kuroyanagi, K. Yamaguchi, Y. Gotoh, K. Irie, T. Kano, K. Shirakabe, Y. Muro, H. Shibuya, K. Matsumoto, et al 1996. A novel kinase cascade mediated by mitogen-activated protein kinase 6 and MKK3. J. Biol. Chem. 271:13675.[Abstract/Free Full Text]
  50. Shirakabe, K., K. Yamaguchi, H. Shibuya, K. Irie, S. Matsuda, T. Moriguchi, Y. Gotoh, K. Matsumoto, E. Nishida. 1997. TAK1 mediates the ceramide signaling to stress-activated protein kinase/c-Jun N-terminal kinase. J. Biol. Chem. 272:8141.[Abstract/Free Full Text]
  51. Shibuya, H., K. Yamaguchi, K. Shirakabe, A. Tonegawa, Y. Gotoh, N. Ueno, K. Irie, E. Nishida, K. Matsumoto. 1996. TAB1: an activator of the TAK1 MAPKKK in TGF-{beta} signal transduction. Science 272:1179.[Abstract]
  52. Yamaguchi, K., K. Sharakabe, H. Shibuya, K. Irie, I. Oishi, N. Ueno, T. Taniguchi, E. Nishida, K. Matsumoto. 1995. Identification of a member of the MAPKKK family as a potential mediator of TGF-{beta} signal transduction. Science 270:2008.[Abstract/Free Full Text]
  53. Ghosh, A. K., W. Yuan, Y. Mori, S. J. Chen, J. Varga. 2001. Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-{beta}: integration at the level of p300/CBP transcriptional coactivators. J. Biol. Chem. 276:11041.[Abstract/Free Full Text]
  54. Mizukami, J., G. Takaesu, H. Akatsuka, H. Sakurai, J. Ninomiya-Tsuji, K. Matsumoto, N. Sakurai. 2002. Receptor activator of NF-{kappa}B lignad (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol. Cell. Biol. 22:992.[Abstract/Free Full Text]
  55. Sakurai, H., H. Miyoshi, W. Toriumi, T. Sugita. 1999. Functional interactions of transforming growth factor {beta}-activated kinase 1 with I{kappa}B kinases stimulate NF-{kappa}B activation. J. Biol. Chem. 274:10641.[Abstract/Free Full Text]
  56. Sakurai, H., N. Shigemori, K. Hasegawa, T. Sugita. 1998. TGF-{beta}-activated kinase 1 stimulates NF-{kappa}B activation by an NF-{kappa}B-inducing kinase-independent mechanism. Biochem. Biophys. Res. Commun. 243:545.[Medline]



This article has been cited by other articles:


Home page
 Infect. Immun.Home page
X. Zhang, M. Alnaeeli, B. Singh, and Y.-T. A. Teng
Involvement of SOCS3 in Regulation of CD11c+ Dendritic Cell-Derived Osteoclastogenesis and Severe Alveolar Bone Loss
Infect. Immun., May 1, 2009; 77(5): 2000 - 2009.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. Lorenzo, M. Horowitz, and Y. Choi
Osteoimmunology: Interactions of the Bone and Immune System
Endocr. Rev., June 1, 2008; 29(4): 403 - 440.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Lee, S.-W. Hyung, H. J. Jung, H.-J. Kim, J. Staerk, S. N. Constantinescu, E.-J. Chang, Z. H. Lee, S.-W. Lee, and H.-H. Kim
The ubiquitin-mediated degradation of Jak1 modulates osteoclastogenesis by limiting interferon- induced inhibitory signaling
Blood, January 15, 2008; 111(2): 885 - 893.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
S. Gentili, J. S. Schwartz, M. J. Waters, and I. C. McMillen
Prolactin and the expression of suppressor of cytokine signaling-3 in the sheep adrenal gland before birth
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2006; 291(5): R1399 - R1405.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Y. Yamamoto, N. Udagawa, S. Matsuura, Y. Nakamichi, H. Horiuchi, A. Hosoya, M. Nakamura, H. Ozawa, K. Takaoka, J. M. Penninger, et al.
Osteoblasts Provide a Suitable Microenvironment for the Action of Receptor Activator of Nuclear Factor-{kappa}B Ligand
Endocrinology, July 1, 2006; 147(7): 3366 - 3374.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Anderson, M. Gries, N. Kurihara, T. Honjo, J. Anderson, V. Donnenberg, A. Donnenberg, I. Ghobrial, M. Y. Mapara, D. Stirling, et al.
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
Blood, April 15, 2006; 107(8): 3098 - 3105.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
D. S. Rakshit, K. Ly, T. K. Sengupta, B. J. Nestor, T. P. Sculco, L. B. Ivashkiv, and P. E. Purdue
Wear Debris Inhibition of Anti-Osteoclastogenic Signaling by Interleukin-6 and Interferon-{gamma} Mechanistic Insights and Implications for Periprosthetic Osteolysis
J. Bone Joint Surg. Am., April 1, 2006; 88(4): 788 - 799.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
K. Janssens, P. ten Dijke, S. Janssens, and W. Van Hul
Transforming Growth Factor-{beta}1 to the Bone
Endocr. Rev., October 1, 2005; 26(6): 743 - 774.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. F. L. Coelho, G. M. de Freitas Almeida, F. J. D. Mennechet, A. Blangy, and G. Uze
Interferon-{alpha} and -{beta} differentially regulate osteoclastogenesis: Role of differential induction of chemokine CXCL11 expression
PNAS, August 16, 2005; 102(33): 11917 - 11922.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
L O'Rear, L Longobardi, M Torello, B K Law, H L Moses, F Chiarelli, and A Spagnoli
Signaling cross-talk between IGF-binding protein-3 and transforming growth factor-{beta} in mesenchymal chondroprogenitor cell growth
J. Mol. Endocrinol., June 1, 2005; 34(3): 723 - 737.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Ohishi, Y. Matsumura, D. Aki, R. Mashima, K. Taniguchi, T. Kobayashi, T. Kukita, Y. Iwamoto, and A. Yoshimura
Suppressors of Cytokine Signaling-1 and -3 Regulate Osteoclastogenesis in the Presence of Inflammatory Cytokines
J. Immunol., March 1, 2005; 174(5): 3024 - 3031.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Rivollier, M. Mazzorana, J. Tebib, M. Piperno, T. Aitsiselmi, C. Rabourdin-Combe, P. Jurdic, and C. Servet-Delprat
Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment
Blood, December 15, 2004; 104(13): 4029 - 4037.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. L. Teitelbaum
Postmenopausal osteoporosis, T cells, and immune dysfunction
PNAS, November 30, 2004; 101(48): 16711 - 16712.
[Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
M. Delgado, D. Pozo, and D. Ganea
The Significance of Vasoactive Intestinal Peptide in Immunomodulation
Pharmacol. Rev., June 1, 2004; 56(2): 249 - 290.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. A. Karsdal, P. Hjorth, K. Henriksen, T. Kirkegaard, K. L. Nielsen, H. Lou, J.-M. Delaisse, and N. T. Foged
Transforming Growth Factor-{beta} Controls Human Osteoclastogenesis through the p38 MAPK and Regulation of RANK Expression
J. Biol. Chem., November 7, 2003; 278(45): 44975 - 44987.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fox, S. W.
Right arrow Articles by Chambers, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fox, S. W.
Right arrow Articles by Chambers, T. J.
Right arrowPubmed/NCBI databases
*Substance via MeSH

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS